LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Advances in Cancer Research, Volume 142, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer… Read more
LIMITED OFFER
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Advances in Cancer Research, Volume 142, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research.
Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology
1. Highly variant DNA methylation in normal tissues identifies a distinct subclass of cancer patientsJayashri Ghosh, Bryant Schultz, Christos Coutifaris and Carmen Sapienza2. Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylationsRyan M. Phillips, Christine Lam, Hailun Wang and Phuoc T. Tran3. The second genome: Effects of the mitochondrial genome on cancer progressionAdam D. Scheid, Thomas C. Beadnell and Danny R. Welch4. Pathways- and epigenetic-based assessment of relative immune infiltration in various types of solid tumorsManny D. Bacolod, Francis Barany, Karsten Pilones, Paul B. Fisher and Romulo J. de Castro5. HVEM network signaling in cancerJohn R. Šedý and Parham Ramezani-Rad6. Pharmacology of ME-344, a novel cytotoxic isoflavoneLeilei Zhang, Jie Zhang, Zhiwei Ye, Danyelle M. Townsend and Kenneth D. Tew
PF
KT
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.